Regenxbio Inc
RGNXHealthcare|Biotechnology|USA
$13.95
-1.71 (-10.92%)
Tangible Book
$0.41
Financials
Financial Snapshot
Market Cap
$721.2M
Enterprise Value
$79.4M
Revenue (TTM)
$87.8M
Net Income (TTM)
$-290.0M
Cash & Equivalents
—
Net Cash/Share
$-3.30
Free Cash Flow (TTM)
$-236.4M
Operating CF (TTM)
$-233.8M
Debt/Equity
3.37
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$58.4M
Monthly Burn
$19.5M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $89.6M | $160.8M | $319.8M | $296.2M | $475.7M | $457.4M | $364.6M | $275.3M | $234.7M | $230.1M | $150.5M | |
| Operating Cash Flow | $-48.6M | $-58.0M | $104.6M | $-107.7M | $-54.1M | $218.9M | $-207.5M | $-218.4M | $-173.1M | $-124.0M | $-233.8M | |
| Free Cash Flow | $-56.7M | $-65.2M | $91.4M | $-119.4M | $-80.9M | $134.7M | $-238.2M | $-228.4M | $-175.6M | $-126.4M | $-236.4M | |
| Capital Expenditure | $-8.1M | $-7.2M | $-13.3M | $-11.7M | $-26.9M | $-84.2M | $-30.7M | $-10.0M | $-2.4M | $-2.4M | $-2.6M | |
| Financing Cash Flow | $119.0K | $84.6M | $204.4M | $8.4M | $200.2M | $195.3M | $-28.8M | $-35.0M | $92.7M | $116.8M | $108.9M |
R&D Spending
R&D (TTM)
$232.6M
R&D Intensity
264.8%
R&D Growth YoY
+1.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $10.4M | $218.5M | $35.2M | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M | $87.8M | |
| R&D Expense | $45.5M | $57.2M | $83.9M | $124.2M | $166.3M | $181.4M | $242.5M | $232.3M | $208.5M | $228.3M | $232.6M | |
| R&D % of Revenue | 991.1% | 550.6% | 38.4% | 352.5% | 107.6% | 38.6% | 215.1% | 257.4% | 250.2% | 133.9% | 264.8% | |
| SG&A | $23.6M | $27.2M | $36.9M | $51.8M | $63.8M | $79.3M | $85.3M | $88.5M | $76.6M | $82.9M | $83.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $10.4M | $218.5M | $35.2M | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M | $87.8M | |
| Cost of Goods Sold | $959.0K | $1.7M | $9.6M | $8.2M | $35.7M | $51.8M | $54.5M | $37.2M | $33.6M | $20.3M | $27.9M | |
| Gross Profit | $3.6M | $8.7M | $208.9M | $27.0M | $118.9M | $418.5M | $58.2M | $53.0M | $49.8M | $150.1M | $59.9M | |
| R&D | $45.5M | $57.2M | $83.9M | $124.2M | $166.3M | $181.4M | $242.5M | $232.3M | $208.5M | $228.3M | $232.6M | |
| SG&A | $23.6M | $27.2M | $36.9M | $51.8M | $63.8M | $79.3M | $85.3M | $88.5M | $76.6M | $82.9M | $83.8M | |
| Operating Income | $-65.3M | $-75.9M | $88.1M | $-149.0M | $-119.2M | $160.0M | $-262.9M | $-268.1M | $-231.2M | $-161.2M | $-256.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $-771.0K | $-26.3M | $-23.3M | $-6.9M | $-12.7M | $-45.0M | $-45.1M | |
| Pretax Income | $-63.4M | $-73.2M | $104.1M | $-97.5M | $-106.0M | $141.2M | $-280.4M | $-263.6M | $-227.1M | $-193.9M | $-290.0M | |
| Net Income | $-63.0M | $-73.2M | $99.9M | $-94.7M | $-111.3M | $127.8M | $-280.3M | $-263.5M | $-227.1M | $-193.9M | $-290.0M | |
| EPS (Diluted) | -2.38 | -2.45 | 2.73 | -2.58 | -2.98 | 2.91 | -6.50 | -6.02 | -4.59 | -3.76 | -5.60 | |
| EBITDA | $-64.8M | $-73.2M | $108.1M | $-90.3M | $-96.8M | $177.1M | $-244.2M | $-239.5M | $-198.2M | $-133.3M | $-229.3M | |
| Shares Out. (M) | 26.41 | 29.88 | 36.65 | 36.69 | 37.28 | 43.91 | 43.15 | 43.73 | 49.51 | 51.57 | 52.43 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.8M | $46.7M | $75.6M | $69.5M | $338.4M | $345.2M | $97.0M | $34.5M | $57.5M | $34.5M | $15.2M | |
| Marketable Securities | $64.7M | $114.1M | $244.2M | $226.7M | $137.3M | $112.2M | $267.7M | $240.7M | $177.2M | $195.6M | $135.3M | |
| Total Current Assets | $93.4M | $168.0M | $337.9M | $345.0M | $531.2M | $518.8M | $416.0M | $335.0M | $278.0M | $281.3M | $186.5M | |
| Total Assets | $172.7M | $198.7M | $543.8M | $497.9M | $708.2M | $1.11B | $833.3M | $574.0M | $466.0M | $453.0M | $341.9M | |
| Total Current Liabilities | $9.7M | $14.4M | $22.2M | $33.7M | $81.4M | $130.5M | $130.4M | $130.3M | $103.2M | $118.1M | $71.1M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $11.0M | $15.6M | $35.0M | $47.7M | $330.4M | $349.6M | $317.1M | $262.2M | $206.3M | $350.3M | $320.8M | |
| Stockholders' Equity | $161.7M | $183.0M | $508.8M | $450.2M | $377.8M | $764.3M | $516.2M | $311.7M | $259.7M | $102.7M | $21.1M | |
| Retained Earnings | $-114.6M | $-187.8M | $-83.0M | $-177.8M | $-289.1M | $-161.2M | $-441.6M | $-705.0M | $-932.1M | $-1.13B | $-1.22B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-48.6M | $-58.0M | $104.6M | $-107.7M | $-54.1M | $218.9M | $-207.5M | $-218.4M | $-173.1M | $-124.0M | $-233.8M | |
| Capital Expenditure | $-8.1M | $-7.2M | $-13.3M | $-11.7M | $-26.9M | $-84.2M | $-30.7M | $-10.0M | $-2.4M | $-2.4M | $-2.6M | |
| Free Cash Flow | $-56.7M | $-65.2M | $91.4M | $-119.4M | $-80.9M | $134.7M | $-238.2M | $-228.4M | $-175.6M | $-126.4M | $-236.4M | |
| Investing Cash Flow | $19.4M | $-4.8M | $-279.4M | $93.6M | $122.8M | $-406.6M | $-11.9M | $190.9M | $103.4M | $-15.9M | $10.0M | |
| Financing Cash Flow | $119.0K | $84.6M | $204.4M | $8.4M | $200.2M | $195.3M | $-28.8M | $-35.0M | $92.7M | $116.8M | $108.9M | |
| Issuance of Stock | $0.00 | $82.5M | $190.6M | $1.3M | $1.8M | $218.2M | $1.7M | $6.7M | $132.3M | $1.0M | $1.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $144.5M | $-33.0K | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $7.0M | $10.6M | $16.6M | $26.9M | $31.9M | $38.8M | $40.8M | $40.3M | $38.5M | $34.6M | $34.6M | |
| Net Change in Cash | $-29.1M | $21.8M | $29.7M | $-5.8M | $268.9M | $7.5M | $-248.3M | $-62.4M | $23.0M | $-23.1M | $-114.9M |
Dilution Tracker
Shares Outstanding
52M
5-Year Share Growth
+19.4%
Stock Issuance (TTM)
$1.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 26.41 | 29.88 | 36.65 | 36.69 | 37.28 | 43.91 | 43.15 | 43.73 | 49.51 | 51.57 | 52.43 | |
| YoY Change % | — | 13.1% | 22.7% | 0.1% | 1.6% | 17.8% | -1.7% | 1.3% | 13.2% | 4.2% | 1.7% | |
| Stock Issuance | $0.00 | $82.5M | $190.6M | $1.3M | $1.8M | $218.2M | $1.7M | $6.7M | $132.3M | $1.0M | $1.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $7.0M | $10.6M | $16.6M | $26.9M | $31.9M | $38.8M | $40.8M | $40.3M | $38.5M | $34.6M | $34.6M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 79.1% | 83.6% | 95.6% | 76.6% | 76.9% | 89.0% | 51.6% | 58.8% | 59.7% | 88.1% | 68.2% | |
| Operating Margin % | -1423.8% | -730.2% | 40.3% | -422.9% | -77.1% | 34.0% | -233.2% | -297.1% | -277.5% | -94.6% | -292.3% | |
| Net Margin % | -1372.1% | -704.0% | 45.7% | -268.9% | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% | -330.2% | |
| EBITDA Margin % | -1412.0% | -704.3% | 49.5% | -256.4% | -62.6% | 37.7% | -216.7% | -265.4% | -237.9% | -78.2% | -261.1% | |
| FCF Margin % | -1235.7% | -626.9% | 41.8% | -339.0% | -52.4% | 28.6% | -211.3% | -253.1% | -210.7% | -74.1% | -269.2% | |
| ROE % | -33.3% | -42.4% | 28.9% | -19.8% | -26.9% | 22.4% | -43.8% | -63.7% | -79.5% | -107.0% | -187.6% | |
| ROA % | -32.0% | -39.4% | 26.9% | -18.2% | -18.4% | 14.0% | -28.8% | -37.4% | -43.7% | -42.2% | -60.6% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 16.21 / 51.62
Industry Med.27.41
P/S8.22
Historical1.92 / 8.84 / 127.01
Industry Med.9.51
P/B34.19
Historical1.07 / 2.83 / 34.19
Industry Med.2.93
EV/EBITDA-2.80
Historical-64.67 / -2.96 / 42.85
Industry Med.13.14
EV/Revenue7.31
Historical0.73 / 7.10 / 108.00
Industry Med.8.71
P/FCF—
Historical8.34 / 17.41 / 439.19
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$0.41
Median P/S Value
$15.81
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | 15.37 | At Loss | At Loss | 11.24 | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | 106.61 | 95.55 | 7.04 | 42.68 | 10.94 | 3.05 | 8.68 | 8.70 | 4.59 | 4.36 | 8.22 | |
| PB Ratio | 3.04 | 5.68 | 2.98 | 3.37 | 4.50 | 1.83 | 1.90 | 2.54 | 1.48 | 7.13 | 34.19 | |
| EV/EBITDA | -6.20 | -12.02 | 11.11 | -13.62 | -13.39 | 5.82 | -2.92 | -2.53 | -1.16 | -4.32 | -2.80 | |
| EV/Revenue | 87.51 | 84.65 | 5.50 | 34.93 | 8.39 | 2.19 | 6.32 | 6.70 | 2.76 | 3.38 | 7.31 |
Analyst Estimates & Quality
Altman Z-Score
-5.33
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
-3.88
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $228.91M | $259.53M | $350.35M |
| Net Income | $-160.32M | $-150.77M | $-140.02M |
| EPS | -3.48 | -2.42 | -2.56 |
| Book Value per Share | 1.88 | 3.65 | -0.58 |
| Operating Cash Flow per Share | -2.27 | 0.99 | 0.00 |
| Operating CF | $-119.01M | $51.90M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Development and commercialization of gene therapies to treat an array of diseases | $170.4M |
By Geography
| Segment | 2025 |
|---|---|
| Japan | $75.0M |
| Other | $52.8M |
| United States | $42.6M |